Answer
Medicines that inhibit or induce CYP enzymes are not expected to affect elotuzumab pharmacokinetics because elotuzumab is not expected to be metabolised by these enzymes, although pharmacokinetic interaction studies have not been conducted.
Sources for this answer
- Empliciti 300 mg and 400 mg powder for concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 12Document updated
Sources checked